Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
Pless S; Woelfle T; Naegelin Y; Lorscheider J; Wiencierz A; Reyes Ó; Calabrese P; Kappos L. Journal of Neurology. 2023.Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis.
Müller J; Schädelin S; Lorscheider J; Benkert P; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Yaldizli Ö. European Journal of Neurology. 2023.Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L. JAMA neurology. 2023.Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
Signori A; Lorscheider J; Vukusic S; Trojano M; Iaffaldano P; Hillert J; Hyde R; Pellegrini F; Magyari M; Koch-Henriksen N; Sørensen PS; Spelman T; van der Walt A; Horakova D; Havrdova E; Girard M; Eichau S; Grand'Maison F; Gerlach O; Terzi M; Ozakbas S; Skibina O; Van Pesch V; Sa MJ; Prevost J; Alroughani R; McCombe PA; Gouider R; Mrabet S; Castillo-Trivino T; Zhu C; de Gans K; Sánchez-Menoyo JL; Yamout B; Khoury S; Sormani MP; Kalincik T; Butzkueven H; Big MS Data Network. Journal of Neurology, Neurosurgery and Psychiatry. 2023.Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration.
Traenka C; Lorscheider J; Hametner C; Baumgartner P; Gralla J; Magoni M; Martinez-Majander N; Casolla B; Feil K; Pascarella R; Papanagiotou P; Nordanstig A; Padjen V; Cereda CW; Psychogios M; Nolte CH; Zini A; Michel P; Béjot Y; Kastrup A; Zedde M; Kägi G; Kellert L; Henon H; Curtze S; Pezzini A; Arnold M; Wegener S; Ringleb P; Tatlisumak T; Nederkoorn PJ; Engelter ST; Gensicke H; EVA-TRISP Collaborators. Journal of stroke. 2023.Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Bühler A; Wolbers M; Model F; Wang Q; Belachew S; Manfrini M; Lorscheider J; Kappos L; Beyersmann J. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
Woelfle T; Pless S; Reyes O; Wiencierz A; Feinstein A; Calabrese P; Gugleta K; Kappos L; Lorscheider J; Naegelin Y. Journal of Neurology. 2023.Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
Meier S.; Willemse E.A.J.; Schaedelin S.; Oechtering J.; Lorscheider J.; Melie-Garcia L.; Cagol A.; Barakovic M.; Galbusera R.; Subramaniam S.; Barro C.; Abdelhak A.; Thebault S.; Achtnichts L.; Lalive P.; Muller S.; Pot C.; Salmen A.; Disanto G.; Zecca C.; D'souza M.; Orleth A.; Khalil M.; Buchmann A.; Du Pasquier R.; Yaldizli O.; Derfuss T.; Berger K.; Hermesdorf M.; Wiendl H.; Piehl F.; Battaglini M.; Fischer U.; Kappos L.; Gobbi C.; Granziera C.; Bridel C.; Leppert D.; Maleska Maceski A.; Benkert P.; Kuhle J.. JAMA neurology. 2023.Synthesizing cross-design evidence and cross-format data using network meta-regression.
Hamza T; Chalkou K; Pellegrini F; Kuhle J; Benkert P; Lorscheider J; Zecca C; Iglesias-Urrutia CP; Manca A; Furukawa TA; Cipriani A; Salanti G. Research synthesis methods. 2023.Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.
Woelfle T; Bourguignon L; Lorscheider J; Kappos L; Naegelin Y; Jutzeler CR. Journal of medical Internet research. 2023.Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C. JAMA neurology. 2022.Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia: A Matched Comparison.
Wagner B; Lorscheider J; Wiencierz A; Blackham K; Psychogios M; Bolliger D; De Marchis GM; Engelter ST; Lyrer P; Wright PR; Fischer U; Mordasini P; Nannoni S; Puccinelli F; Kahles T; Bianco G; Carrera E; Luft AR; Cereda CW; Kägi G; Weber J; Nedeltchev K; Michel P; Gralla J; Arnold M; Bonati LH; Swiss Stroke Registry Investigators. Stroke. 2022.Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. The Lancet Neurology. 2022.Accurate classification of secondary progression in multiple sclerosis using a decision tree.
Ramanujam R; Zhu F; Fink K; Karrenbauer VD; Lorscheider J; Benkert P; Kingwell E; Tremlett H; Hillert J; Manouchehrinia A; BeAMS Study group. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Acute Polyradiculomyelitis With Spinal Cord Gray Matter Lesions: A Report of Two Cases.
Tsagkas C; Wendebourg MJ; Mehling M; Lorscheider J; Lyrer P; Décard BF. Frontiers in Neurology. 2021.Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
Fischer-Barnicol B.; Oechtering J.; Kuhle J.; Lorscheider J.; Kappos L.; Derfuss T.. Neurology(R) neuroimmunology & neuroinflammation. 2021.Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Journal of Neurology. 2021.Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study.
Woelfle T; Pless S; Wiencierz A; Kappos L; Naegelin Y; Lorscheider J. Journal of medical Internet research. 2021.When does a heap become a heap?
Lorscheider J. . 2021.Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.
D'Souza M; Heikkilä A; Lorscheider J; Haller V; Kravalis K; Gysin S; Fuertes NAC; Fricker E; Lam E; Higgins P; Tomic D; Papadopoulou A; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.
von Wyl V; Décard BF; Benkert P; Lorscheider J; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. European Journal of Neurology. 2020.A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T; MSBase Study Group. European Journal of Neurology. 2019.Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T. JAMA neurology. 2019.Hypothyroidism manifesting as multiple cranial neuropathies: a case report.
Hepprich M; Lorscheider J; Peters N; Betz MJ. Journal of medical case reports. 2019.PML with dimethyl fumarate-No convincing case against natalizumab.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T; MSBase Study Group. Neurology. 2017.Defining secondary progressive multiple sclerosis.
Lorscheider J; Buzzard K; Jokubaitis V; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Alroughani R; Sola P; Boz C; Pucci E; Lechner-Scott J; Bergamaschi R; Oreja-Guevara C; Iuliano G; Van Pesch V; Granella F; Ramo-Tello C; Spitaleri D; Petersen T; Slee M; Verheul F; Ampapa R; Amato MP; McCombe P; Vucic S; Sánchez Menoyo JL; Cristiano E; Barnett MH; Hodgkinson S; Olascoaga J; Saladino ML; Gray O; Shaw C; Moore F; Butzkueven H; Kalincik T; MSBase Study Group. Brain. 2016.Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Jokubaitis VG; Spelman T; Kalincik T; Lorscheider J; Havrdova E; Horakova D; Duquette P; Girard M; Prat A; Izquierdo G; Grammond P; Van Pesch V; Pucci E; Grand'Maison F; Hupperts R; Granella F; Sola P; Bergamaschi R; Iuliano G; Spitaleri D; Boz C; Hodgkinson S; Olascoaga J; Verheul F; McCombe P; Petersen T; Rozsa C; Lechner-Scott J; Saladino ML; Farina D; Iaffaldano P; Paolicelli D; Butzkueven H; Lugaresi A; Trojano M; MSBase Study Group. Annals of Neurology. 2016.The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options
Disanto G.; Benkert P.; Lorscheider J.; Mueller S.; Vehoff J.; Zecca C.; Ramseier S.; Achtnichts L.; Findling O.; Nedeltchev K.; Radue E.-W.; Sprenger T.; Stippich C.; Derfuss T.; Louvion J.-F.; Kamm C.P.; Mattle H.P.; Lotter C.; Du Pasquier R.; Schluep M.; Pot C.; Lalive P.H.; Yaldizli O.; Gobbi C.; Kappos L.; Kuhle J.; Saxer J.; Remonda L.; Boxheimer L.; Limberg M.; Scheerer I.; Orleth A.; Treppke F.; Beregi E.; Reinhardt J.; Fellner I.; Wurfel J.; Thoeni A.; Palatini A.; Pauli-Magnus C.; Fabbro T.; Roesler A.; Mechati S.; Chan A.; Salmen A.; Kaeser M.; Wagner F.; Verma R.; Di Marco M.; Haller S.; Lovblad K.-O.; Granziera C.; Hagmann P.; Maeder P.; Tschuor S.; Cianfoni A.; Weber J.. PLoS ONE. 2016.Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L. Neurology. 2015.T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin,Meret E; Lorscheider,Johannes; Waschbisch,Anne; Paroz,Cecile; Mehta,Satish K; Pierson,Duane L; Kuhle,Jens; Fischer-Barnicol,Bettina; Sprenger,Till; Lindberg,Raija L P; Kappos,Ludwig; Derfuss,Tobias. Neurology. 2013.The BAR domain protein PICK1 regulates cell recognition and morphogenesis by interacting with Neph proteins.
Höhne M; Lorscheider J; von Bardeleben A; Dufner M; Scharf MA; Gödel M; Helmstädter M; Schurek EM; Zank S; Gerke P; Kurschat C; Sivritas SH; Neumann-Haefelin E; Huber TB; Reinhardt HC; Schauss AC; Schermer B; Fischbach KF; Benzing T. Molecular and Cellular Biology. 2011.